- Home
- OPP vs ARMP Comparison
OPP vs ARMP Comparison
Compare OPP & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPP | ARMP |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.4M | 156.4M |
| IPO Year | 2016 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OPP | ARMP |
|---|---|---|
| Price | $7.67 | $4.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 79.8K | ★ 146.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.47 | $2.40 |
| 52 Week High | $8.77 | $14.98 |
Technical Indicators
Market Signals| Indicator | OPP | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 47.49 |
| Support Level | $7.50 | $4.51 |
| Resistance Level | $7.74 | $5.60 |
| Average True Range (ATR) | 0.08 | 0.52 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 79.93 | 48.41 |
Price Performance
Historical ComparisonAbout OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.